HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mary Beth Dorr Selected Research

bezlotoxumab

11/2021Efficacy of Bezlotoxumab in Trial Participants Infected With Clostridioides difficile Strain BI Associated With Poor Outcomes.
10/2020Analysis of C. difficile infection-related outcomes in European participants in the bezlotoxumab MODIFY I and II trials.
6/2020Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection.
2/2020Exploratory Evaluation of Bezlotoxumab on Outcomes Associated With Clostridioides difficile Infection in MODIFY I/II Participants With Cancer.
2/2020Bezlotoxumab for prevention of Clostridium difficile infection recurrence: Distinguishing relapse from reinfection with whole genome sequencing.
1/2020Genetic Association Reveals Protection against Recurrence of Clostridium difficile Infection with Bezlotoxumab Treatment.
1/2020Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: 12-Month Observational Data From the Randomized Phase III Trial, MODIFY II.
1/2020Assessment of Bezlotoxumab Immunogenicity.
1/2020A time-to-event analysis of the exposure-response relationship for bezlotoxumab concentrations and CDI recurrence.
8/2019Influence of Diagnostic Method on Outcomes in Phase 3 Clinical Trials of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: A Post Hoc Analysis of MODIFY I/II.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Mary Beth Dorr Research Topics

Disease

18Clostridium Infections
11/2021 - 01/2016
6Infections
10/2020 - 03/2005
1Reinfection
02/2020
1Neoplasms (Cancer)
02/2020
1Invasive Candidiasis
01/2020
1Candidiasis (Moniliasis)
01/2020
1Osteomyelitis
01/2020
1Body Weight (Weight, Body)
01/2019
1Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
10/2018
1Atrophic Vaginitis
11/2010
1Granuloma
03/2005
1Blister (Bulla)
03/2004
1Soft Tissue Infections
11/2003
1Ototoxicity
04/2003

Drug/Important Bio-Agent (IBA)

17bezlotoxumabIBA
11/2021 - 10/2017
4Monoclonal AntibodiesIBA
11/2021 - 01/2019
3Anti-Bacterial Agents (Antibiotics)IBA
10/2020 - 04/2003
2Metronidazole (Metric)FDA LinkGeneric
06/2020 - 02/2018
2VancomycinFDA LinkGeneric
06/2020 - 02/2018
2actoxumabIBA
01/2020 - 02/2018
2Pharmaceutical PreparationsIBA
10/2017 - 03/2004
2dalbavancinIBA
03/2005 - 11/2003
2GlycopeptidesIBA
11/2003 - 04/2003
1FidaxomicinIBA
06/2020
1NucleotidesIBA
02/2020
1deoxycholate drug combination amphotericin BIBA
01/2020
1DaptomycinFDA Link
01/2020
1Caspofungin (Cancidas)FDA Link
01/2020
1AntibodiesIBA
01/2016
1Biomarkers (Surrogate Marker)IBA
01/2016
1Conjugated (USP) Estrogens (Premarin)FDA Link
11/2010
1Estrogens (Estrogen)FDA Link
11/2010
1TabletsIBA
11/2010

Therapy/Procedure

4Therapeutics
01/2020 - 11/2003
2Patient Readmission
11/2018 - 10/2017